Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.
Kristie L. Kahl
Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.
The FDA has accepted the supplemental biologics license application and granted breakthrough therapy designation to nivolumab plus ipilimumab for the treatment of patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2‐positive metastatic breast cancer.
MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.
Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.
The agency approved the first and only FDA-approved erythroid maturation agent to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.
The FDA approved a biosimilar to pegfilgrastim, called LA-EP2006 to decrease the incidence of infection, exhibited from febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer therapy that is associated with a clinically significant incidence of febrile neutropenia.
While there have been increases in the amount of thyroid cancer cases detected, there is still work for oncologists to do – namely to ensure there is adequate evaluation of the disease at diagnosis.
The National Comprehensive Cancer Network recently issued new guidelines on best practices in evaluating patients for hematopoietic cell transplantation, as well as how to manage complications associated with the procedure.